Guangzhou Boji Medical and Biotechnological Co Ltd (300404) - Total Assets
Based on the latest financial reports, Guangzhou Boji Medical and Biotechnological Co Ltd (300404) holds total assets worth CN¥1.56 Billion CNY (≈ $228.86 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Guangzhou Boji Medical and Biotechnologi book value and equity for net asset value and shareholders' equity analysis.
Guangzhou Boji Medical and Biotechnological Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Guangzhou Boji Medical and Biotechnological Co Ltd's total assets have evolved over time, based on quarterly financial data.
Guangzhou Boji Medical and Biotechnological Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangzhou Boji Medical and Biotechnological Co Ltd's total assets of CN¥1.56 Billion consist of 53.8% current assets and 46.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.6% |
| Accounts Receivable | CN¥169.70 Million | 11.7% |
| Inventory | CN¥189.49 Million | 13.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥21.32 Million | 1.5% |
| Goodwill | CN¥28.10 Million | 1.9% |
Asset Composition Trend (2012–2024)
This chart illustrates how Guangzhou Boji Medical and Biotechnological Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Guangzhou Boji Medical and Biotechnologi.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangzhou Boji Medical and Biotechnological Co Ltd's current assets represent 53.8% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2024, down from 41.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 13.1% of total assets.
Guangzhou Boji Medical and Biotechnological Co Ltd Competitors by Total Assets
Key competitors of Guangzhou Boji Medical and Biotechnological Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Guangzhou Boji Medical and Biotechnological Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.15 | 1.69 |
| Quick Ratio | 1.35 | 1.60 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥417.23 Million | CN¥453.71 Million | CN¥141.07 Million |
Guangzhou Boji Medical and Biotechnological Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangzhou Boji Medical and Biotechnological Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.02 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | CN¥1.45 Billion |
| Market Capitalization | $606.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangzhou Boji Medical and Biotechnological Co Ltd's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guangzhou Boji Medical and Biotechnological Co Ltd's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guangzhou Boji Medical and Biotechnological Co Ltd (2012–2024)
The table below shows the annual total assets of Guangzhou Boji Medical and Biotechnological Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.45 Billion ≈ $212.27 Million |
+1.52% |
| 2023-12-31 | CN¥1.43 Billion ≈ $209.10 Million |
+12.92% |
| 2022-12-31 | CN¥1.27 Billion ≈ $185.17 Million |
+11.18% |
| 2021-12-31 | CN¥1.14 Billion ≈ $166.56 Million |
+51.84% |
| 2020-12-31 | CN¥749.63 Million ≈ $109.69 Million |
+18.41% |
| 2019-12-31 | CN¥633.08 Million ≈ $92.64 Million |
+4.47% |
| 2018-12-31 | CN¥606.02 Million ≈ $88.68 Million |
+5.45% |
| 2017-12-31 | CN¥574.72 Million ≈ $84.10 Million |
+10.77% |
| 2016-12-31 | CN¥518.85 Million ≈ $75.92 Million |
-0.25% |
| 2015-12-31 | CN¥520.15 Million ≈ $76.11 Million |
+67.65% |
| 2014-12-31 | CN¥310.26 Million ≈ $45.40 Million |
+5.66% |
| 2013-12-31 | CN¥293.64 Million ≈ $42.97 Million |
+25.81% |
| 2012-12-31 | CN¥233.40 Million ≈ $34.15 Million |
-- |
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch … Read more